Plague vaccine injectable - DynPort/USAMRIID

Alternative Names: Recombinant F1V plague vaccine - Dynport Vaccine Company; rF1V vaccine

Latest Information Update: 17 Mar 2017

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator United States Army Medical Research Institute of Infectious Diseases
Developer DynPort Vaccine Company
Class Plague vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Yersinia infections
New Molecular Entity No

17 Mar 2017 Plague vaccine injectable is still in phase II trials for prevention of Yersinia infections in USA
08 Mar 2017 Plague vaccine injectable - DynPort/USAMRIID receives Orphan Drug status for Yersinia infections in USA
22 Aug 2012 DynPort completes a phase II trial in Healthy volunteers in US (NCT01122784)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com